Browsing by Autor "Jhonny Limachi-Choque"

Now showing 1 - 8 of 8

Anticoagulantes Orais Diretos versus Antagonistas da Vitamina K para Trombo Ventricular Esquerdo: Uma Metanálise com Análise Sequencial de Ensaios
(Sociedade Brasileira de Cardiologia (SBC), 2024) Eric Pasqualotto; Douglas Mesadri Gewehr; Rafael Oliva Morgado Ferreira; Matheus Pedrotti Chavez; Caroliny Silva; Sara Almeida Cruz; Jhonny Limachi-Choque; Amanda Park; Mário Sérgio Soares de Azeredo Coutinho; Luiz Fernando Kubrusly
DOACs had a similar rate of thromboembolic and hemorrhagic events, as well as thrombus resolution, compared to VKAs in the treatment of LVTs. Rivaroxaban therapy had a significant reduction in thromboembolic events, compared to VKAs.
Anticuerpos Anti SARS-CoV-2, Post-vacunación en Cochabamba, Bolivia
(2022) Jhonny Limachi-Choque; Aleida Verduguez Orellana
Objetivo: evaluar la presencia de anticuerpos contra la proteína específica de la espiga (RBD, dominio de unión al receptor de la proteína de espícula) y NP (nucleoproteína) del virus SARS-CoV-2 en personas que recibieron vacunas anti COVID-19 empleadas en Bolivia. Métodos: durante el año 2021 entre los meses de julio y agosto, se realizó un estudio observacional de tipo transversal, en 150 personas de ambos sexos que fueron reclutadas en los Hospitales: Caja de Seguro Social Militar y Caja Nacional de Salud, para detectar anticuerpos específicos contra las proteínas NP y RBD del virus SARS-CoV-2 responsable de la COVID-19, mediante una prueba inmunocromatográfica cualitativa. Resultados: la presencia de anticuerpos neutralizantes posterior a la aplicación de vacunas contra SARS-CoV-2, como esquema completo, primera dosis, y/o el antecedente de infección, se encontró en el 61 % de las personas agrupadas en la categoría “bajo riesgo laboral” de forma heterogénea en lo referente a anticuerpos RBD, NP o ambas juntas. Conclusiones: la producción de anticuerpos contra la proteína específica de la espiga RBD y NP del virus SARS-CoV-2 muestra una respuesta heterogénea por varios factores como ser, tipo de vacuna, numero de dosis, infección por el COVID-19, disminución de anticuerpo a largo del tiempo, sensibilidad del test y las propiedades intrínsecas de la persona evaluada.
Direct Oral Anticoagulants versus Vitamin K Antagonists for Left Ventricular Thrombus: A Meta-Analysis with Trial Sequential Analysis
(Sociedade Brasileira de Cardiologia (SBC), 2024) Eric Pasqualotto; Douglas Mesadri Gewehr; Rafael Oliva Morgado Ferreira; Matheus Pedrotti Chavez; Caroliny Silva; Sara Almeida Cruz; Jhonny Limachi-Choque; Amanda Park; Mário Sérgio Soares de Azeredo Coutinho; Luiz Fernando Kubrusly
Abstract Background Vitamin K antagonists (VKAs) are the recommended first-line treatment for left ventricular thrombus (LVT); however, direct oral anticoagulants (DOACs) have been considered an alternative therapy. Objectives To evaluate the efficacy and safety of DOACs compared with VKAs therapy in patients with LVT. Methods PubMed, Embase, and Cochrane were systematically searched for randomized clinical trials or cohort studies that compared DOACs versus VKAs for LVT. Risk ratios (RRs) were computed for binary endpoints, with 95% confidence intervals (95% CIs). Statistical significance was defined as p value < 0.05. Results A total of 4 randomized clinical trials and 29 cohort studies were included, with 4,450 patients assigned to either DOACs or VKAs. There was no significant difference between groups for stroke or systemic embolic (SSE) events (RR 0.84; 95% CI 0.65 to 1.07; p = 0.157), stroke (RR 0.73; 95% CI 0.48 to 1.11; p = 0.140), systemic embolic (SE) events (RR 0.69; 95% CI 0.40 to 1.17; p = 0.166), thrombus resolution (RR 1.05; 95% CI 0.99 to 1.11; p = 0.077), any bleeding (RR 0.78; 95% CI 0.60 to 1.00; p = 0.054), clinically relevant bleeding (RR 0.69; 95% CI 0.46 to 1.03; p = 0.066), minor bleeding (RR 0.73; 95% CI 0.43 to 1.23; p = 0.234), major bleeding (RR 0.87; 95% CI 0.42 to 1.80; p = 0.705), and all-cause mortality (RR 1.05; 95% CI 0.79 to 1.39; p = 0.752). Compared with VKAs, rivaroxaban significantly reduced SSE events (RR 0.35; 95% CI 0.16 to 0.91; p = 0.029) and SE events (RR 0.39; 95% CI 0.16 to 0.95; p = 0.037). Conclusions DOACs had a similar rate of thromboembolic and hemorrhagic events, as well as thrombus resolution, compared to VKAs in the treatment of LVTs. Rivaroxaban therapy had a significant reduction in thromboembolic events, compared to VKAs.
Efficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
(Springer Science+Business Media, 2024) Francisco Cézar Aquino de Moraes; Anna Luíza Soares de Oliveira Rodrigues; Jonathan N. Priantti; Jhonny Limachi-Choque; Rommel Mário Rodríguez Burbano
Ethnic disparities in survival and progression among EGFR-mutated adenocarcinoma of lung cancer patients treated with tyrosine kinase inhibitors: a systematic review and meta-analysis
(Springer Science+Business Media, 2025) Francisco Cézar Aquino de Moraes; Anna Luíza Soares de Oliveira Rodrigues; Eric Pasqualotto; Jéssica Fernanda Cassemiro; Jhonny Limachi-Choque; Rommel Mário Rodríguez Burbano
Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia
(Multidisciplinary Digital Publishing Institute, 2022) Ernesto Rojas Cabrera; Aleida Verduguez-Orellana; Igberto J. Tordoya-Titichoca; Ccoya Sejas; Rebeca Ledezma; Ingrid Álvarez; Jhonny Limachi-Choque; Nimer Ortuño‐Gutiérrez; Marisol Córdova Rojas; Miguel Guzmán-Rivero
The standard of care for cutaneous leishmaniasis includes the intramuscular/intravenous administration of pentavalent antimonials that are toxic and poorly tolerated. Primary health care usually lacks trained health staff for the diagnosis and treatment of leishmaniasis in Cochabamba Bolivia. Taking these aspects into account, a Bolivian consortium set out to explore the intralesional administration of meglumine antimoniate to treat cutaneous leishmaniasis during primary care under programmatic conditions. A four-step strategy consisting of clinical training for intralesional treatment and the promotion and periodic follow-up of health staff was carried out. The training process was applied in situ to personnel of nine primary health care centres. The intralesional treatment was applied five times every other day. Clinical follow-up after six-months of treatment showed a 77% healing proportion and 5% of therapeutic failure among 152 enrolled patients. The drug volume used in the intralesional procedure was on average 1.7 mL/ulcer treated. In conclusion, the strategy used was successful and effective, accomplishing a healing proportion similar to the long standardized treatment with a reduced time of administration, no severe side effects, and it is feasible to conduct by trained health staff. Our study supports the current PAHO/WHO recommendation for the intralesional administration of pentavalent antimonials for the treatment of cutaneous leishmaniasis.
Risk factors for COVID-19 mortality in hospitalized patients in Bolivia
(Elsevier BV, 2023) Jhonny Limachi-Choque; Javier Guitián; Christine Leyns; Miguel Guzmán-Rivero; Daniel Eid Rodríguez
Termoterapia versus tratamiento intralesional para leishmaniasis cutánea: Un metaanálisis de ensayos clínicos controlados
(2024) Jhonny Limachi-Choque; Endjel Braga-Heinzmann; Lizbeth Choque-Asquicho; Patrícia Marcolin; Kevin Fallaza-Moya
Objetivo: Evaluar la eficacia de la termoterapia para el tratamiento de la leishmaniasis cutánea en comparación con el tratamiento intralesional. Material y métodos: Realizamos una revisión sistemática de ensayos clínicos, evaluando los dos tratamientos para la leishmaniasis cutanea. Llevamos a cabo búsquedas estructuradas en PubMed, Embase, Cochrane y LILACS. No se aplicaron restricciones en cuanto a etnia, país, sexo o año de publicación. Los idiomas se limitaron a inglés, español y portugués. Dos revisores examinaron los artículos, completaron la extracción de datos y otros dos evaluaron el riesgo de sesgo. Se realizó un resumen cualitativo de los estudios incluidos. Resultados: Se incluyeron 5 estudios y 958 pacientes. La curación clínica de termoterapia fue de 77,7% a comparación de tratamiento intralesional que fue 71,1%, y se evidencio diferencia entre los dos grupos (odds ratio [OR] 1.42; intervalo de confianza [IC] del 95%: 1,05-1,90). Conclusión: La termoterapia presento una mayor eficacia al tratamiento intralesional en el tratamiento de la leishmaniasis cutánea en términos de curación clínica en los estudios del Viejo Mundo. Palabras Clave: Leishmaniasis cutánea, termoterapia, tratamiento intralesional